Highlights

  • The Q4 FY26 Business update, released on 29 July 2026 alongside an investor webinar hosted by chief executive Teri Thomas and interim…
  • Mach7 reported Operating Cash Flow of AUD 1.1 million for the June quarter, its third straight positive quarter.
  • On the product side, Flamingo recorded its first production deployment, at US health system UnityPoint Health. eUnity was listed on the Epic…
  • Management reaffirmed FY26 guidance: Revenue approximately 15% below FY25, reflecting historical customer losses and delayed international Capital deals, with operating expenses roughly…

Mach7 Technologies has spent FY26 doing something unglamorous but necessary: shrinking its cost base and defending Recurring Revenue after two customer losses knocked a hole in its contracted book. The July quarterly showed the reset is producing cash. The audited full-year numbers due this month will show whether it is producing a business.

Company Overview

Mach7 sells medical imaging software to hospitals and health networks, principally in North America. Its core product is an enterprise imaging platform built around a vendor neutral archive, or VNA, which consolidates images from radiology, cardiology, pathology and other departments that would otherwise sit in separate proprietary silos. Alongside that sits eUnity, a zero-footprint diagnostic viewer radiologists use to read studies through a browser rather than a dedicated workstation.

Recent Developments

The Q4 FY26 business update, released on 29 July 2026 alongside an investor webinar hosted by chief executive Teri Thomas and interim chief financial officer Shawni Hadfield, gave the clearest read yet on the reset.

Mach7 reported operating cash flow of AUD 1.1 million for the June quarter, its third straight positive quarter. Cash rose about 4% sequentially to AUD 19.9 million with no Debt . Operating payments fell 7.3% quarter on quarter on lower staff and administrative costs, while customer cash receipts of roughly AUD 7.1 million were down 7.9% on Q3, which management attributed to payment timing rather than softer Demand .

Financial Snapshot

The recurring revenue base is the number that matters. At 30 June 2026 Mach7 reported an ARR run rate of AUD 23.5 million, up 7.6% in constant currency on 30 June 2025. Contracted annual recurring revenue stood at AUD 25.5 million, up AUD 0.9 million on the March quarter but down 8.9% year on year on the company's stated basis, the decline…

For context, FY25 delivered revenue of AUD 33.8 million, up 16%, with recurring revenue of AUD 25.3 million representing 75% of the total and covering about 80% of operating expenses. Adjusted EBITDA was negative AUD 0.3 million and NPATA was AUD 0.4 million, on a closing cash balance of AUD 23.1 million. The company also bought back 6.3 million shares for AUD…

What to Watch

The FY26 preliminary final report and audited financial statements, expected in the second half of August, are the immediate catalyst, with any FY27 guidance the key variable. The Annual Report is scheduled for late October 2026 per Mach7's corporate calendar, with the interim report following in February 2027. Beyond the calendar, watch for conversion of the Epic listing into named customer wins…

Risks

Mach7's contracted revenue is concentrated in a modest number of large hospital customers, and the FY26 experience shows how much a single non-renewal can move the aggregate. Guidance for revenue 15% below FY25 is itself a reminder that capital deal timing in international markets remains unpredictable.

Outlook

Mach7 enters its August result with a cleaner cost base, positive operating cash flow and a debt-free Balance Sheet , offset by a contracted book that shrank over the year. What investors will focus on is FY27: whether recurring revenue growth outpaces FY26's contract attrition, and whether the Epic and channel partnerships translate into signed orders. The August disclosure…